{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:23Z","timestamp":1789635743787,"version":"4.0.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02113-0","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:09:26Z","timestamp":1787036966000},"page":"3189-3203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanobodies Open New Avenues in Cancer Treatment: From Molecular Engineering to Therapeutic Platforms"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0172-5041","authenticated-orcid":false,"given":"Glenda","family":"Romero-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1587","authenticated-orcid":false,"given":"Mario S.","family":"Vald\u00e9s-Tresanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-4826","authenticated-orcid":false,"given":"Ernesto","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"5517","key":"2113_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495\u2013497. https:\/\/doi.org\/10.1038\/256495a0.","journal-title":"Nature"},{"issue":"3","key":"2113_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ABT\/TBAF014","volume":"8","author":"WR Strohl","year":"2025","unstructured":"Strohl, W. R. (2025). Structure and function of therapeutic antibodies approved by the US FDA in 2024. Antibody Therapeutics, 8(3), 197\u2013237. https:\/\/doi.org\/10.1093\/ABT\/TBAF014.","journal-title":"Antibody Therapeutics"},{"issue":"6","key":"2113_CR3","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"B Jin","year":"2023","unstructured":"Jin, B., Odongo, S., Radwanska, M., & Magez, S. (2023). NANOBODIES\u00ae: A review of generation, diagnostics and therapeutics. International Journal of Molecular Sciences, 24(6), 5994 https:\/\/doi.org\/10.3390\/ijms24065994.","journal-title":"International Journal of Molecular Sciences"},{"key":"2113_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02900-y","volume":"22","author":"E Alexander","year":"2024","unstructured":"Alexander, E., & Leong, K. W. (2024). Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. Journal of Nanobiotechnology, 22, 661 https:\/\/doi.org\/10.1186\/s12951-024-02900-y.","journal-title":"Journal of Nanobiotechnology"},{"issue":"10","key":"2113_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","volume":"25","author":"AC Chan","year":"2025","unstructured":"Chan, A. C., Martyn, G. D., & Carter, P. J. (2025). Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nature reviews. Immunology, 25(10), 745\u2013765. https:\/\/doi.org\/10.1038\/s41577-025-01207-9.","journal-title":"Nature reviews. Immunology"},{"issue":"6428","key":"2113_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., & Hamers, R. (1993). Naturally occurring antibodies devoid of light chains. Nature, 363(6428), 446\u2013448. https:\/\/doi.org\/10.1038\/363446a0.","journal-title":"Nature"},{"key":"2113_CR7","unstructured":"Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler Communications Biology. (n.d.). Retrieved from https:\/\/www.nature.com\/articles\/s42003-026-09594-y"},{"issue":"1\u20133","key":"2113_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","volume":"128","author":"S Muyldermans","year":"2009","unstructured":"Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., Rothbauer, U., Stijlemans, B., Tillib, S., Wernery, U., Wyns, L., Hassanzadeh-Ghassabeh, G., & Saerens, D. (2009). Camelid immunoglobulins and nanobody technology. Veterinary Immunology and Immunopathology, 128(1\u20133), 178\u2013183. https:\/\/doi.org\/10.1016\/j.vetimm.2008.10.299.","journal-title":"Veterinary Immunology and Immunopathology"},{"key":"2113_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. (2013). Nanobodies: natural single-domain antibodies. Annual Review of Biochemistry, 82, 775\u2013797. https:\/\/doi.org\/10.1146\/annurev-biochem-063011-092449.","journal-title":"Annual Review of Biochemistry"},{"issue":"7","key":"2113_CR10","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.3390\/MOLECULES27072198","volume":"27","author":"MS Vald\u00e9s-Tresanco","year":"2022","unstructured":"Vald\u00e9s-Tresanco, M. S., Molina-Zapata, A., Pose, A. G., & Moreno, E. (2022). Structural insights into the design of synthetic nanobody libraries. Molecules, 27(7), 2198 https:\/\/doi.org\/10.3390\/MOLECULES27072198.","journal-title":"Molecules"},{"issue":"4","key":"2113_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/V17040571\/S1","volume":"17","author":"M Maltseva","year":"2025","unstructured":"Maltseva, M., Rossotti, M. A., Tanha, J., & Langlois, M. A. (2025). Characterization of nanobody binding to distinct regions of the SARS-CoV-2 spike protein by flow virometry. Viruses, 17(4), 571 https:\/\/doi.org\/10.3390\/V17040571\/S1.","journal-title":"Viruses"},{"issue":"5","key":"2113_CR12","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41596-020-0304-x","volume":"15","author":"I Zimmermann","year":"2020","unstructured":"Zimmermann, I., Egloff, P., Hutter, C. A. J. J., Kuhn, B. T., Br\u00e4uer, P., Newstead, S., Dawson, R. J. P., Geertsma, E. R., & Seeger, M. A. (2020). Generation of synthetic nanobodies against delicate proteins. Nature Protocols, 15(5), 1707\u20131741. https:\/\/doi.org\/10.1038\/s41596-020-0304-x.","journal-title":"Nature Protocols"},{"key":"2113_CR13","doi-asserted-by":"publisher","first-page":"e34317","DOI":"10.7554\/ELIFE.34317","volume":"7","author":"I Zimmermann","year":"2018","unstructured":"Zimmermann, I., Egloff, P., Hutter, C. A. J., Arnold, F. M., Stohler, P., Bocquet, N., Hug, M. N., Huber, S., Siegrist, M., Hetemann, L., Gera, J., Gm\u00fcr, S., Spies, P., Gygax, D., Geertsma, E. R., Dawson, R. J., & Seeger, M. A. (2018). Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife, 7, e34317 https:\/\/doi.org\/10.7554\/ELIFE.34317.","journal-title":"eLife"},{"issue":"11","key":"2113_CR14","doi-asserted-by":"publisher","first-page":"28218","DOI":"10.1371\/journal.pone.0028218","volume":"6","author":"G Hussack","year":"2011","unstructured":"Hussack, G., Hirama, T., Ding, W., Mackenzie, R., & Tanha, J. (2011). Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS ONE, 6(11), 28218 https:\/\/doi.org\/10.1371\/journal.pone.0028218.","journal-title":"PLoS ONE"},{"key":"2113_CR15","doi-asserted-by":"publisher","unstructured":"Goldman, E. R., Liu, J. L., Zabetakis, D., & Anderson, G. P. (2017, July 25). Enhancing stability of camelid and shark single domain antibodies: An overview. Frontiers in Immunology. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fimmu.2017.00865","DOI":"10.3389\/fimmu.2017.00865"},{"key":"2113_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113852","volume":"383","author":"B Qiu","year":"2025","unstructured":"Qiu, B., Pompe, S., Xenaki, K. T., Di Maggio, A., Moreno, C. B., van Bergen En Henegouwen, P. M. P., Mastrobattista, E., Oliveira, S., & Caiazzo, M. (2025). Receptor-mediated transcytosis of nanobodies targeting the heparin-binding EGF-like growth factor in human blood-brain barrier models. Journal of Controlled Release, 383, 113852 https:\/\/doi.org\/10.1016\/j.jconrel.2025.113852.","journal-title":"Journal of Controlled Release"},{"issue":"3","key":"2113_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ymthe.2005.04.003","volume":"12","author":"TW Miller","year":"2005","unstructured":"Miller, T. W., & Messer, A. (2005). Intrabody applications in neurological disorders: Progress and future prospects. Molecular Therapy, 12(3), 394\u2013401. https:\/\/doi.org\/10.1016\/j.ymthe.2005.04.003.","journal-title":"Molecular Therapy"},{"issue":"181","key":"2113_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-3-540-73259-4_15","volume":"181","author":"ASY Lo","year":"2008","unstructured":"Lo, A. S. Y., Zhu, Q., & Marasco, W. A. (2008). Intracellular antibodies (intrabodies) and their therapeutic potential. Handbook of Experimental Pharmacology, 181(181), 343\u2013373. https:\/\/doi.org\/10.1007\/978-3-540-73259-4_15.","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"7","key":"2113_CR19","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/FEBS.15515","volume":"288","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans, S. (2021). A guide to: generation and design of nanobodies. The FEBS journal, 288(7), 2084 https:\/\/doi.org\/10.1111\/FEBS.15515.","journal-title":"The FEBS journal"},{"issue":"5","key":"2113_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/biology14050547","volume":"14","author":"H Zhu","year":"2025","unstructured":"Zhu, H., & Ding, Y. (2025). Nanobodies: From discovery to AI-Driven design. Biology (Basel), 14(5), 547 https:\/\/doi.org\/10.3390\/biology14050547.","journal-title":"Biology (Basel)"},{"key":"2113_CR21","doi-asserted-by":"publisher","first-page":"584604","DOI":"10.2147\/IJN.S584604","volume":"21","author":"N Ghosh","year":"2026","unstructured":"Ghosh, N., Sepay, N., Paul, M., & Im, J. (2026). Nanobody-based drug delivery: Emerging strategies for targeted cancer therapy. International journal of nanomedicine, 21, 584604 https:\/\/doi.org\/10.2147\/IJN.S584604.","journal-title":"International journal of nanomedicine"},{"issue":"10","key":"2113_CR22","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1039\/D5NH00283D","volume":"10","author":"M Blueggel","year":"2025","unstructured":"Blueggel, M., G\u00fcl, D., Stauber, R. H., & Knauer, S. K. (2025). Small but mighty: the versatility of nanobodies in modern medicine. Nanoscale Horiz, 10(10), 2158\u20132171. https:\/\/doi.org\/10.1039\/D5NH00283D.","journal-title":"Nanoscale Horiz"},{"key":"2113_CR23","unstructured":"Cancer Research Institute. (2025). CRI Cancer Immunotherapy Insights + Impact Report. https:\/\/www.cancerresearch.org\/cancer-immunotherapy-report-2025"},{"key":"2113_CR24","doi-asserted-by":"publisher","unstructured":"Jain, A., & Stebbing, J. (2025). The relationship between response rate and survival benefits in randomized immunotherapy studies. Cancers, 17(3). https:\/\/doi.org\/10.3390\/cancers17030495","DOI":"10.3390\/cancers17030495"},{"key":"2113_CR25","doi-asserted-by":"publisher","first-page":"S1234","DOI":"10.1016\/j.annonc.2024.08.2284","volume":"35","author":"J Larkin","year":"2024","unstructured":"Larkin, J., Sileni, V. C., Marqueste, C. G., Rutkowski, P., Medina, T. M., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Queirolo, P., Walker, J., Butler, M. O., Hill, A. G., Marquez-Rodas, I., Haanen, J. B. A. G., Nassar, A., Askelson, M., Hodi, F. S., & Wolchok, J. D. (2024). LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. Annals of Oncology, 35, S1234\u2013S1235. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2284.","journal-title":"Annals of Oncology"},{"issue":"15","key":"2113_CR26","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","volume":"78","author":"S Duggan","year":"2018","unstructured":"Duggan, S. (2018). Caplacizumab: First global approval. Drugs, 78(15), 1639\u20131642. https:\/\/doi.org\/10.1007\/s40265-018-0989-0.","journal-title":"Drugs"},{"issue":"1","key":"2113_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., Schallier, D., Fontaine, C., Vaneycken, I., Vanhove, C., De Greve, J., Lamote, J., Caveliers, V., & Lahoutte, T. (2016). Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. Journal of Nuclear Medicine, 57(1), 27\u201333. https:\/\/doi.org\/10.2967\/jnumed.115.162024.","journal-title":"Journal of Nuclear Medicine"},{"issue":"8","key":"2113_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1021\/polymscitech.5c00080","volume":"1","author":"Y Yuan","year":"2025","unstructured":"Yuan, Y., Zhuoga, C., Zeng, C., Zhou, W., Chen, W., Zhen, X., & Jiang, X. (2025). Advances in nanobody-based platforms for precision cancer diagnosis and therapy. Polymer Science & Technology, 1(8), 692\u2013715. https:\/\/doi.org\/10.1021\/polymscitech.5c00080.","journal-title":"Polymer Science & Technology"},{"issue":"1","key":"2113_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00699-3","volume":"8","author":"H Cheng","year":"2024","unstructured":"Cheng, H., Xu, H., Peng, B., Huang, X., Hu, Y., Zheng, C., & Zhang, Z. (2024). Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence. npj Precision Oncology, 8(1), 196 https:\/\/doi.org\/10.1038\/s41698-024-00699-3.","journal-title":"npj Precision Oncology"},{"issue":"1","key":"2113_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-023-06382-3","volume":"16","author":"B Kakasi","year":"2023","unstructured":"Kakasi, B., G\u00e1csi, E., Jankovics, H., & Vonderviszt, F. (2023). Extreme thermal stability of the antiGFP nanobody - GFP complex. BMC Research Notes, 16(1), 110 https:\/\/doi.org\/10.1186\/s13104-023-06382-3.","journal-title":"BMC Research Notes"},{"issue":"12","key":"2113_CR31","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/pro.519","volume":"19","author":"MH Kubala","year":"2010","unstructured":"Kubala, M. H., Kovtun, O., Alexandrov, K., & Collins, B. M. (2010). Structural and thermodynamic analysis of the GFP:GFP-nanobody complex. Protein Science, 19(12), 2389\u20132401. https:\/\/doi.org\/10.1002\/pro.519.","journal-title":"Protein Science"},{"key":"2113_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.synbio.2025.12.006","volume":"12","author":"Y Chen","year":"2025","unstructured":"Chen, Y., Wang, S., Xie, L., Zhang, L., Zhu, M., & Xu, Y. (2025). Design principles for optogenetic-based targeted protein degradation. Synthetic and Systems Biotechnology, 12, 255\u2013264. https:\/\/doi.org\/10.1016\/j.synbio.2025.12.006.","journal-title":"Synthetic and Systems Biotechnology"},{"issue":"1","key":"2113_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma, W., Xue, R., Zhu, Z., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023). Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology & Oncology, 12(1), 10 https:\/\/doi.org\/10.1186\/s40164-023-00372-8.","journal-title":"Experimental Hematology & Oncology"},{"issue":"3","key":"2113_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","volume":"56","author":"RC Roovers","year":"2007","unstructured":"Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007). Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunology, Immunotherapy : CII, 56(3), 303\u2013317. https:\/\/doi.org\/10.1007\/s00262-006-0180-4.","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"issue":"1","key":"2113_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1042\/BCJ20180795","volume":"476","author":"MA Rossotti","year":"2019","unstructured":"Rossotti, M. A., Henry, K. A., van Faassen, H., Tanha, J., Callaghan, D., Hussack, G., Arbabi-Ghahroudi, M., & MacKenzie, C. R. (2019). Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling. The Biochemical Journal, 476(1), 39\u201350. https:\/\/doi.org\/10.1042\/BCJ20180795.","journal-title":"The Biochemical Journal"},{"issue":"42","key":"2113_CR36","doi-asserted-by":"publisher","first-page":"13843","DOI":"10.1002\/anie.201807736","volume":"57","author":"S Guardiola","year":"2018","unstructured":"Guardiola, S., Varese, M., S\u00e1nchez-Navarro, M., Vincke, C., Teixid\u00f3, M., Garc\u00eda, J., Muyldermans, S., & Giralt, E. (2018). Blocking EGFR activation with Anti-EGF nanobodies via two distinct molecular recognition mechanisms. Angewandte Chemie (International ed. in English), 57(42), 13843\u201313847. https:\/\/doi.org\/10.1002\/anie.201807736.","journal-title":"Angewandte Chemie (International ed. in English)"},{"issue":"1","key":"2113_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/antib8010025","volume":"8","author":"H Wang","year":"2019","unstructured":"Wang, H., Wang, Y., Xiao, Z., Li, W., Dimitrov, D. S., & Chen, W. (2019). Human domain antibodies to conserved epitopes on HER2 potently inhibit growth of HER2-Overexpressing human breast cancer cells in vitro. Antibodies (Basel), 8(1), 25 https:\/\/doi.org\/10.3390\/antib8010025.","journal-title":"Antibodies (Basel)"},{"issue":"19","key":"2113_CR38","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3390\/ijms20194818","volume":"20","author":"G Sadeghnezhad","year":"2019","unstructured":"Sadeghnezhad, G., Rom\u00e3o, E., Bernedo-Navarro, R., Massa, S., Khajeh, K., Muyldermans, S., & Hassania, S. (2019). Identification of new DR5 agonistic nanobodies and generation of multivalent nanobody constructs for cancer treatment. International Journal of Molecular Sciences, 20(19), 4818 https:\/\/doi.org\/10.3390\/ijms20194818.","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"2113_CR39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/1535-7163.MCT-11-0891","volume":"11","author":"MJWD Vosjan","year":"2012","unstructured":"Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., Stigter-van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012). Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Molecular Cancer Therapeutics, 11(4), 1017\u20131025. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0891.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"34","key":"2113_CR40","doi-asserted-by":"publisher","first-page":"13791","DOI":"10.1073\/pnas.1300013110","volume":"110","author":"D S\u00e1nchez-Mart\u00edn","year":"2013","unstructured":"S\u00e1nchez-Mart\u00edn, D., Mart\u00ednez-Torrecuadrada, J., Teesalu, T., Sugahara, K. N., Alvarez-Cienfuegos, A., Xim\u00e9nez-Emb\u00fan, P., Fern\u00e1ndez-Peri\u00e1\u00f1ez, R., Mart\u00edn, M. T., Molina-Privado, I., Ruppen-Ca\u00f1\u00e1s, I., Blanco-Toribio, A., Ca\u00f1amero, M., Cuesta, A. M., Compte, M., Kremer, L., Bellas, C., Alonso-Camino, V., Guijarro-Mu\u00f1oz, I., Sanz, L., & Alvarez-Vallina, L. (2013). Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. Proceedings of the National Academy of Sciences of the United States of America, 110(34), 13791\u201313796. https:\/\/doi.org\/10.1073\/pnas.1300013110.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"27","key":"2113_CR41","doi-asserted-by":"publisher","first-page":"11452","DOI":"10.1074\/jbc.M116.774141","volume":"292","author":"L Schoonaert","year":"2017","unstructured":"Schoonaert, L., Ru\u00e9, L., Roucourt, B., Timmers, M., Little, S., Ch\u00e1vez-Guti\u00e9rrez, L., Dewilde, M., Joyce, P., Curnock, A., Weber, P., Haustraete, J., Hassanzadeh-Ghassabeh, G., De Strooper, B., Van Den Bosch, L., Van Damme, P., Lemmens, R., & Robberecht, W. (2017). Identification and characterization of Nanobodies targeting the EphA4 receptor. The Journal of Biological Chemistry, 292(27), 11452\u201311465. https:\/\/doi.org\/10.1074\/jbc.M116.774141.","journal-title":"The Journal of Biological Chemistry"},{"issue":"25","key":"2113_CR42","doi-asserted-by":"publisher","first-page":"17282","DOI":"10.18632\/oncotarget.24629","volume":"9","author":"N Samec","year":"2018","unstructured":"Samec, N., Jovcevska, I., Stojan, J., Zottel, A., Liovic, M., Myers, M. P., Muyldermans, S., \u0160ribar, J., Kri\u017eaj, I., & Komel, R. (2018). Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting. Oncotarget, 9(25), 17282\u201317299. https:\/\/doi.org\/10.18632\/oncotarget.24629.","journal-title":"Oncotarget"},{"issue":"10","key":"2113_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41422-019-0225-9","volume":"29","author":"D Wang","year":"2019","unstructured":"Wang, D., Hu, X., Liu, C., Jia, Y., Bai, Y., Cai, C., Wang, J., Bai, L., Yang, R., Lin, C., Liu, Y. R., Li, S., Qiao, F., Yao, L., Chen, L., Ge, G., Jiang, H., Li, D., Li, L., & Zeng, Y. A. (2019). Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. Cell Research, 29(10), 832\u2013845. https:\/\/doi.org\/10.1038\/s41422-019-0225-9.","journal-title":"Cell Research"},{"issue":"2","key":"2113_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3892\/or.2017.6131","volume":"39","author":"R Wan","year":"2018","unstructured":"Wan, R., Liu, A., Hou, X., Lai, Z., Li, J., Yang, N., Tan, J., Mo, F., Hu, Z., Yang, X., Zhao, Y., & Lu, X. (2018). Screening and antitumor effect of an anti-CTLA-4 nanobody. Oncology Reports, 39(2), 511\u2013518. https:\/\/doi.org\/10.3892\/or.2017.6131.","journal-title":"Oncology Reports"},{"issue":"1","key":"2113_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41551-025-01447-z","volume":"10","author":"X Liu","year":"2025","unstructured":"Liu, X., Le Gall, C., Alexander, R. K., Borgman, E., Balligand, T., & Ploegh, H. L. (2025). Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy. Nature Biomedical Engineering, 10(1), 39\u201355. https:\/\/doi.org\/10.1038\/s41551-025-01447-z.","journal-title":"Nature Biomedical Engineering"},{"issue":"2","key":"2113_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbrc.2020.07.072","volume":"531","author":"L Ma","year":"2020","unstructured":"Ma, L., Gai, J., Qiao, P., Li, Y., Li, X., Zhu, M., Li, G., & Wan, Y. (2020). A novel bispecific nanobody with PD-L1\/TIGIT dual immune checkpoint blockade. Biochemical and Biophysical Research Communications, 531(2), 144\u2013151. https:\/\/doi.org\/10.1016\/j.bbrc.2020.07.072.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"2113_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1377874","volume":"7","author":"SL Harwood","year":"2017","unstructured":"Harwood, S. L., Alvarez-Cienfuegos, A., Nu\u00f1ez-Prado, N., Compte, M., Hern\u00e1ndez-P\u00e9rez, S., Merino, N., Bonet, J., Navarro, R., Van Bergen En Henegouwen, P. M. P., Lykkemark, S., Mikkelsen, K., M\u00f8lgaard, K., Jabs, F., Sanz, L., Blanco, F. J., Roda-Navarro, P., & Alvarez-Vallina, L. (2017). ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology, 7(1), e1377874 https:\/\/doi.org\/10.1080\/2162402X.2017.1377874.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2113_CR48","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acs.biochem.4c00793","volume":"64","author":"Y Chen","year":"2025","unstructured":"Chen, Y., & van Hoa, F. (2025). Peptidisc-assisted hydrophobic clustering toward the production of multimeric and multispecific nanobody proteins. Biochemistry, 64(3), 655\u2013665. https:\/\/doi.org\/10.1021\/acs.biochem.4c00793.","journal-title":"Biochemistry"},{"issue":"1","key":"2113_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-0571-2","volume":"18","author":"L Ma","year":"2020","unstructured":"Ma, L., Zhu, M., Gai, J., Li, G., Chang, Q., Qiao, P., Cao, L., Chen, W., Zhang, S., & Wan, Y. (2020). Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. Journal of Nanobiotechnology, 18(1), 12 https:\/\/doi.org\/10.1186\/s12951-020-0571-2.","journal-title":"Journal of Nanobiotechnology"},{"issue":"1","key":"2113_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bbrc.2014.02.069","volume":"446","author":"Z Farajpour","year":"2014","unstructured":"Farajpour, Z., Rahbarizadeh, F., Kazemi, B., & Ahmadvand, D. (2014). A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. Biochemical and Biophysical Research Communications, 446(1), 132\u2013136. https:\/\/doi.org\/10.1016\/j.bbrc.2014.02.069.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"9","key":"2113_CR51","doi-asserted-by":"publisher","first-page":"e1189","DOI":"10.1093\/oncolo\/oyae102","volume":"29","author":"C Cui","year":"2024","unstructured":"Cui, C., Wang, J., Wang, C., Xu, T., Qin, L., Xiao, S., Gong, J., Song, L., & Liu, D. (2024). Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors. The Oncologist, 29(9), e1189\u2013e1200. https:\/\/doi.org\/10.1093\/oncolo\/oyae102.","journal-title":"The Oncologist"},{"key":"2113_CR52","doi-asserted-by":"publisher","unstructured":"Xu, D., Wang, H., Bao, Q., Jin, K., Liu, M., Liu, W., Yan X., Wang L., Zhang Y., Wang G., Ma Y., Ma Z., Zhang C., Tang J., Wang S., Pang J., Xu T., Wang K., Xing, B. (2025). The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial. Nature Communications, 16(1). https:\/\/doi.org\/10.1038\/s41467-025-56537-y","DOI":"10.1038\/s41467-025-56537-y"},{"issue":"7","key":"2113_CR53","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1080\/21691401.2017.1369426","volume":"46","author":"F Khodabakhsh","year":"2018","unstructured":"Khodabakhsh, F., Norouzian, D., Vaziri, B., Ahangari Cohan, R., Sardari, S., Mahboudi, F., Behdani, M., Mansouri, K., & Mehdizadeh, A. (2018). Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. Artificial Cells Nanomedicine Biotechnology, 46(7), 1402\u20131414. https:\/\/doi.org\/10.1080\/21691401.2017.1369426.","journal-title":"Artificial Cells Nanomedicine Biotechnology"},{"issue":"5","key":"2113_CR54","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/08923973.2018.1505907","volume":"40","author":"R Baharlou","year":"2018","unstructured":"Baharlou, R., Tajik, N., Behdani, M., Shokrgozar, M. A., Tavana, V., Kazemi-Lomedasht, F., Faraji, F., & Habibi-Anbouhi, M. (2018). An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization. Immunopharmacology and Immunotoxicology, 40(5), 368\u2013374. https:\/\/doi.org\/10.1080\/08923973.2018.1505907.","journal-title":"Immunopharmacology and Immunotoxicology"},{"issue":"18","key":"2113_CR55","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2217\/imt-2019-0068","volume":"11","author":"AS Khatibi","year":"2019","unstructured":"Khatibi, A. S., Roodbari, N. H., Majidzade-A, K., Yaghmaei, P., & Farahmand, L. (2019). In vivo tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3\u03b5 nanobody in breast cancer mice model. Immunotherapy, 11(18), 1555\u20131567. https:\/\/doi.org\/10.2217\/imt-2019-0068.","journal-title":"Immunotherapy"},{"issue":"6","key":"2113_CR56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/gt.2017.30","volume":"24","author":"C Goyvaerts","year":"2017","unstructured":"Goyvaerts, C., De Vlaeminck, Y., Escors, D., Lienenklaus, S., Keyaerts, M., Raes, G., & Breckpot, K. (2017). Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: Implications for in vivo targeted vaccine delivery. Gene Therapy, 24(6), 370\u2013375. https:\/\/doi.org\/10.1038\/gt.2017.30.","journal-title":"Gene Therapy"},{"issue":"3","key":"2113_CR57","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/vaccines14030239","volume":"14","author":"Q Liu","year":"2026","unstructured":"Liu, Q., Liu, Y., Li, J., Huang, S., Chen, Z., Li, J., Wang, T., Zhou, P., Huo, J., & Li, D. (2026). A precision-engineered DC-Targeting mRNA-LNP neoantigen vaccine elicits stronger T cell responses and exhibits superior tumor control. Vaccines (Basel), 14(3), 239 https:\/\/doi.org\/10.3390\/vaccines14030239.","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"2113_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201088","volume":"33","author":"F Meeus","year":"2025","unstructured":"Meeus, F., der Vreken, A., Autaers, D., De Groof, T. W. M., Esprit, A., Franceschini, L., Parone, P., Goyvaerts, C., De Vlaeminck, Y., Devoogdt, N., & Breckpot, K. (2025). Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors. Molecular Therapy Oncology, 33(4), 201088 https:\/\/doi.org\/10.1016\/j.omton.2025.201088.","journal-title":"Molecular Therapy Oncology"},{"issue":"1","key":"2113_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-025-01756-5","volume":"18","author":"A der Vreken","year":"2025","unstructured":"der Vreken, A., Meeus, F., Tu, C., van den Broecke, L., Raimondi, V., Vescovini, R., Hanssens, H., Watt\u00e9, F., Autaers, D., Aragon, M. M., Billiau, J., De Veirman, K., Vanderkerken, K., De Vlaeminck, Y., Franceschini, L., Lee, H., Neri, P., De Bruyne, E., Storti, P., & Menu, E. (2025). B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA\/B7-H3 CAR T cells overcome antigen escape. Journal of Hematology & Oncology, 18(1), 103 https:\/\/doi.org\/10.1186\/s13045-025-01756-5.","journal-title":"Journal of Hematology & Oncology"},{"key":"2113_CR60","unstructured":"Mei H.. (2024). A Multicenter Clinical Study on the Safety and Efficacy of Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of Relapsed\/Refractory Multiple Myeloma. https:\/\/clinicaltrials.gov. Wuhan, Hubei, China. Retrieved April 29, 2026, from https:\/\/clinicaltrials.gov"},{"issue":"2","key":"2113_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/1871527317666181114134518","volume":"18","author":"T Sadeghian-Rizi","year":"2019","unstructured":"Sadeghian-Rizi, T., Behdani, M., Khanahmad, H., Sadeghi, H. M., & Jahanian-Najafabadi, A. (2019). Generation and characterization of a functional nanobody against inflammatory chemokine CXCL10, as a Novel strategy for the treatment of multiple sclerosis. CNS & neurological disorders drug targets, 18(2), 141\u2013148. https:\/\/doi.org\/10.2174\/1871527317666181114134518.","journal-title":"CNS & neurological disorders drug targets"},{"issue":"4","key":"2113_CR62","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1021\/acs.bioconjchem.6c00045","volume":"37","author":"OT Choy","year":"2026","unstructured":"Choy, O. T., Fletcher, N. L., Huda, P., Bell, C. A., Owen, D. J., & Whittaker, A. K. (2026). Lipid nanoparticles with side-chain polymer coating for targeted mRNA delivery through nanobody attachment. Bioconjugate Chemistry, 37(4), 684\u2013692. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00045.","journal-title":"Bioconjugate Chemistry"},{"issue":"Pt 2","key":"2113_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.148626","volume":"333","author":"MK Al-Khafaji","year":"2025","unstructured":"Al-Khafaji, M. K., Rahbarizadeh, F., & Ahmadvand, D. (2025). Oligoclonal anti-HER2 nanobody-targeted exosomes as a nano carrier for doxorubicin delivery to HER2-positive breast cancer in vitro and in vivo. International Journal of Biological Macromolecules, 333(Pt 2), 148626 https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148626.","journal-title":"International Journal of Biological Macromolecules"},{"issue":"3","key":"2113_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/ANTIB4030141","volume":"4","author":"S Hoefman","year":"2015","unstructured":"Hoefman, S., Ottevaere, I., Baumeister, J., & Sargentini-Maier, M. L. (2015). Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies\u00ae. Antibodies, 4(3), 141\u2013156. https:\/\/doi.org\/10.3390\/ANTIB4030141.","journal-title":"Antibodies"},{"issue":"7","key":"2113_CR65","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1021\/ACS.BIOCONJCHEM.2C00209","volume":"33","author":"B Hu","year":"2022","unstructured":"Hu, B., Liu, T., Li, L., Shi, L., Yao, M., Li, C., Ma, X., Zhu, H., Jia, B., & Wang, F. (2022). IgG-binding nanobody capable of prolonging nanobody-based radiotracer plasma half-life and enhancing the efficacy of tumor-targeted radionuclide therapy. Bioconjugate Chemistry, 33(7), 1328\u20131339. https:\/\/doi.org\/10.1021\/ACS.BIOCONJCHEM.2C00209.","journal-title":"Bioconjugate Chemistry"},{"issue":"4","key":"2113_CR66","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","volume":"7","author":"A Klarenbeek","year":"2015","unstructured":"Klarenbeek, A., El Mazouari, K., Desmyter, A., Blanchetot, C., Hultberg, A., de Jonge, N., Roovers, R. C., Cambillau, C., Spinelli, S., Del-Favero, J., Verrips, T., de Haard, H. J., & Achour, I. (2015). Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. mAbs, 7(4), 693\u2013706. https:\/\/doi.org\/10.1080\/19420862.2015.1046648.","journal-title":"mAbs"},{"issue":"1","key":"2113_CR67","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s42003-026-09594-y","volume":"9","author":"GL Gordon","year":"2026","unstructured":"Gordon, G. L., Gervasio, J., Souders, C., & Deane, C. M. (2026). Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler. Communications Biology, 9(1), 344 https:\/\/doi.org\/10.1038\/s42003-026-09594-y.","journal-title":"Communications Biology"},{"issue":"5","key":"2113_CR68","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","volume":"75","author":"KP Papadopoulos","year":"2015","unstructured":"Papadopoulos, K. P., Isaacs, R., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D., Kundamal, N., Tang, Z., Cooksey, J., & Mahipal, A. (2015). Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody\u00ae targeting the DR5 receptor. Cancer Chemotherapy and Pharmacology, 75(5), 887\u2013895. https:\/\/doi.org\/10.1007\/s00280-015-2712-0.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"2113_CR69","doi-asserted-by":"publisher","first-page":"e1287246","DOI":"10.1080\/2162402X.2017.1287246","volume":"6","author":"S Albert","year":"2017","unstructured":"Albert, S., Arndt, C., Feldmann, A., Bergmann, R., Bachmann, D., Koristka, S., Koristka, S., Ludwig, F., Ziller-Walter, P., Kegler, A., G\u00e4rtner, S., Schmitz, M., Ehninger, A., Cartellieri, M., Ehninger, G., Pietzsch, H. J., Pietzsch, J., Steinbach, J., & Bachmann, M. (2017). A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunology, 6(4), e1287246 https:\/\/doi.org\/10.1080\/2162402X.2017.1287246.","journal-title":"Oncoimmunology"},{"key":"2113_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1163392","author":"S Wasti","year":"2023","unstructured":"Wasti, S., Lee, I. H., Kim, S., Lee, J. H., & Kim, H. (2023). Ethical and legal challenges in nanomedical innovations: a scoping review. Frontiers in Genetics. https:\/\/doi.org\/10.3389\/fgene.2023.1163392.","journal-title":"Frontiers in Genetics"},{"key":"2113_CR71","doi-asserted-by":"publisher","unstructured":"Bocancia-Mateescu, L.-A., Stan, D., Mirica, A.-C., Ghita, M. G., Stan, D., & Ruta, L. L. (2023). Nanobodies as diagnostic and therapeutic tools for cardiovascular diseases (CVDs). Pharmaceuticals, 16(6). https:\/\/doi.org\/10.3390\/ph16060863","DOI":"10.3390\/ph16060863"},{"issue":"3","key":"2113_CR72","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmb.2005.07.038","volume":"352","author":"D Saerens","year":"2005","unstructured":"Saerens, D., Pellis, M., Loris, R., Pardon, E., Dumoulin, M., Matagne, A., Wyns, L., Muyldermans, S., & Conrath, K. (2005). Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. Journal of Molecular Biology, 352(3), 597\u2013607. https:\/\/doi.org\/10.1016\/j.jmb.2005.07.038.","journal-title":"Journal of Molecular Biology"},{"issue":"8095","key":"2113_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","volume":"649","author":"NR Bennett","year":"2026","unstructured":"Bennett, N. R., Watson, J. L., Ragotte, R. J., Borst, A. J., See, D. L., Weidle, C., Biswas, R., Yu, Y., Shrock, E. L., Ault, R., Leung, P. J. Y., Huang, B., Goreshnik, I., Tam, J., Carr, K. D., Singer, B., Criswell, C., Wicky, B. I. M., Vafeados, D., & Baker, D. (2026). Atomically accurate de novo design of antibodies with RFdiffusion. Nature, 649(8095), 183\u2013193. https:\/\/doi.org\/10.1038\/s41586-025-09721-5.","journal-title":"Nature"},{"key":"2113_CR74","doi-asserted-by":"publisher","first-page":"1545136","DOI":"10.3389\/FCHEM.2025.1545136\/TEXT","volume":"13","author":"X Wang","year":"2025","unstructured":"Wang, X., Chen, H., Chen, B., Liang, L., Mei, F., & Huang, B. (2025). NanoAbLLaMA: construction of nanobody libraries with protein large language models. Frontiers in Chemistry, 13, 1545136 https:\/\/doi.org\/10.3389\/FCHEM.2025.1545136\/TEXT.","journal-title":"Frontiers in Chemistry"},{"key":"2113_CR75","doi-asserted-by":"publisher","unstructured":"Zhang, Y., & Tsuda, K. (2025). NbBench: Benchmarking language models for comprehensive nanobody tasks. Machine Learning: Science and Technology, 6(4). https:\/\/doi.org\/10.1088\/2632-2153\/ae20ec","DOI":"10.1088\/2632-2153\/ae20ec"},{"key":"2113_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-025-02991-x","author":"V Marx","year":"2026","unstructured":"Marx, V. (2026). What nanobodies can do for you. Nature methods. https:\/\/doi.org\/10.1038\/s41592-025-02991-x.","journal-title":"Nature methods"},{"issue":"9","key":"2113_CR77","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","volume":"411","author":"J-P Salvador","year":"2019","unstructured":"Salvador, J.-P., Vilaplana, L., & Marco, M.-P. (2019). Nanobody: outstanding features for diagnostic and therapeutic applications. Analytical and bioanalytical chemistry, 411(9), 1703\u20131713. https:\/\/doi.org\/10.1007\/s00216-019-01633-4.","journal-title":"Analytical and bioanalytical chemistry"},{"issue":"12","key":"2113_CR78","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.0505379103","volume":"103","author":"E De Genst","year":"2006","unstructured":"De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006). Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proceedings of the National Academy of Sciences of the United States of America, 103(12), 4586\u20134591. https:\/\/doi.org\/10.1073\/pnas.0505379103.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"2113_CR79","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-23-0189","volume":"11","author":"LA King","year":"2023","unstructured":"King, L. A., Toffoli, E. C., Veth, M., Iglesias-Guimarais, V., Slot, M. C., Amsen, D., van de Ven, R., Derks, S., Fransen, M. F., Tuynman, J. B., Riedl, T., Roovers, R. C., Adang, A. E. P., Ruben, J. M., Parren, P. W. H. I., de Gruijl, T. D., & Van Der Vliet, H. J. (2023). A bispecific \u03b3\u03b4 T-cell engager targeting EGFR activates a potent V\u03b39V\u03b42 T cell-Mediated immune response against EGFR-expressing tumors. Cancer Immunology Research, 11(9), 1237\u20131252. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0189.","journal-title":"Cancer Immunology Research"},{"issue":"12_Supplement","key":"2113_CR80","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1158\/1538-7445.AM2022-2857","volume":"82","author":"Y Fang","year":"2022","unstructured":"Fang, Y., Yao, G., Zhong, W., Duan, W., Zhou, Z., Wen, X., Chen, Y., Fang, J., Wang, Y., Jiang, W., Xu, J., & Huang, Y. (2022). Abstract 2857: DR30303, a SMART-VHHBody powered anti-CLDN18.2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers. Cancer Research, 82(12_Supplement), 2857 https:\/\/doi.org\/10.1158\/1538-7445.AM2022-2857.","journal-title":"Cancer Research"},{"issue":"41","key":"2113_CR81","doi-asserted-by":"publisher","first-page":"16642","DOI":"10.1073\/pnas.1202832109","volume":"109","author":"JAJM van de Water","year":"2012","unstructured":"van de Water, J. A. J. M., Bagci-Onder, T., Agarwal, A. S., Wakimoto, H., Roovers, R. C., Zhu, Y., Kasmieh, R., Bhere, D., Van Bergen en Henegouwen, P. M., & Shah, K. (2012). Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 109(41), 16642\u201316647. https:\/\/doi.org\/10.1073\/pnas.1202832109.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"2113_CR82","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10637-022-01287-7","volume":"40","author":"T Shimizu","year":"2022","unstructured":"Shimizu, T., Nakajima, T. E., Yamamoto, N., Yonemori, K., Koyama, T., Kondo, S., Sunakawa, Y., Izawa, N., Horie, Y., Xiang, S., Xu, S., Qin, L., Gong, J., & Liu, D. (2022). Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. Investigational New Drugs, 40(5), 1021\u20131031. https:\/\/doi.org\/10.1007\/s10637-022-01287-7.","journal-title":"Investigational New Drugs"},{"issue":"1","key":"2113_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"J Li","year":"2021","unstructured":"Li, J., Deng, Y., Zhang, W., Zhou, A.-P., Guo, W., Yang, J., Yuan, Y., Zhu, L., Qin, S., Xiang, S., Lu, H., Gong, J., Xu, T., Liu, D., & Shen, L. (2021). Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. Journal of Hematology & Oncology, 14(1), 95 https:\/\/doi.org\/10.1186\/s13045-021-01095-1.","journal-title":"Journal of Hematology & Oncology"},{"issue":"9","key":"2113_CR84","doi-asserted-by":"publisher","first-page":"e1514","DOI":"10.1002\/onco.13817","volume":"26","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos, K. P., Harb, W., Peer, C. J., Hua, Q., Xu, S., Lu, H., Lu, N., He, Y., Xu, T., Dong, R., Gong, J., & Liu, D. (2021). First-in-Human phase I study of envafolimab, a novel subcutaneous single-domain Anti-PD-L1 antibody, in patients with advanced solid tumors. The oncologist, 26(9), e1514\u2013e1525. https:\/\/doi.org\/10.1002\/onco.13817.","journal-title":"The oncologist"},{"issue":"8","key":"2113_CR85","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","volume":"62","author":"M D\u2019Huyvetter","year":"2021","unstructured":"D\u2019Huyvetter, M., De Vos, J., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., Aa, F. V., Hendrikse, N. H., Eersels, J. L. E., Everaert, H., Gykiere, P., Devoogdt, N., Raes, G., Lahoutte, T., & Keyaerts, M. (2021). Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-Targeted radionuclide therapy in breast cancer patients. Journal of Nuclear Medicine, 62(8), 1097\u20131105. https:\/\/doi.org\/10.2967\/jnumed.120.255679.","journal-title":"Journal of Nuclear Medicine"},{"key":"2113_CR86","doi-asserted-by":"publisher","first-page":"1544967","DOI":"10.3389\/fonc.2025.1544967","volume":"15","author":"R Ramlau","year":"2025","unstructured":"Ramlau, R., Kowalski, D. M., Szcz\u0119sna, A., Szczylik, C., Ou, Y., K\u00f6bel, M., Siegers, G. M., Gaspar, K. J., Lee, B., & Roszkowski-Sliz, K. (2025). Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I\/II monotherapy study targeting advanced NSCLC. Frontiers in Oncology, 15, 1544967 https:\/\/doi.org\/10.3389\/fonc.2025.1544967.","journal-title":"Frontiers in Oncology"},{"issue":"11","key":"2113_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100408","volume":"3","author":"S Piha-Paul","year":"2022","unstructured":"Piha-Paul, S., Simon, G., Belani, C. P., Chao, H., Gaspar, K., Lee, B., & Dowlati, A. (2022). A Phase 1, open-label, dose-escalation study of L-DOS47 in combination with pemetrexed plus carboplatin in patients with stage IV recurrent or metastatic nonsquamous NSCLC. JTO Clinical and Research Reports, 3(11), 100408 https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100408.","journal-title":"JTO Clinical and Research Reports"},{"key":"2113_CR88","doi-asserted-by":"publisher","unstructured":"Kater, A. P., Van De Donk, N. W. C. J., Rodr\u00edguez-Otero, P., Mateos, M. V., Bosch, F., Tucci, A., Ghia P., Adang A. E. P., Parren P. W. H. I., Tuinhof I., Umarale S., Winograd B., Van Der Vliet H. J., Broijl, A. (2022). Lava-051, a novel bispecific gamma-delta T-Cell engager (Gammabody), in relapsed\/refractory MM and CLL: Pharmacodynamic and early clinical data. Blood, 140(Supplement 1). https:\/\/doi.org\/10.1182\/blood-2022-166851","DOI":"10.1182\/blood-2022-166851"},{"key":"2113_CR89","doi-asserted-by":"publisher","unstructured":"Gondry, O., Caveliers, V., Xavier, C., Raes, L., Vanhoeij, M., Verfaillie, G., Fontaine C., Glorieus K., De Gr\u00e8ve J., Joris S., Luyten I., Zwaenepoel K., Vandenbroucke F., Waelput W., Thyparambil S., Vaneycken I., Cousaert J., Bourgeois S., Bourgeois S.\u2026Keyaerts, M. (2024). Phase II trial assessing the repeatability and tumor uptake of [68Ga]Ga-HER2 single-domain antibody PET\/CT in patients with breast carcinoma. Journal of Nuclear Medicine, 65(2). https:\/\/doi.org\/10.2967\/jnumed.123.266254","DOI":"10.2967\/jnumed.123.266254"},{"key":"2113_CR90","unstructured":"JPRN-jRCT2031230019. (2023). A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031230019."},{"key":"2113_CR91","doi-asserted-by":"publisher","first-page":"112936","DOI":"10.1016\/j.ejca.2023.05.024","volume":"190","author":"A Xiong","year":"2023","unstructured":"Xiong, A., Li, W., Li, X., Fan, Y., Ma, Z., Fang, J., Xie, Q., Zhuang, W., Kang, M., Wang, J., Xu, T., Xu, M., Zhi, L., Liu, Q., Wang, N., & Zhou, C. (2023). Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. European Journal of Cancer, 190, 112936 https:\/\/doi.org\/10.1016\/j.ejca.2023.05.024.","journal-title":"European Journal of Cancer"},{"key":"2113_CR92","unstructured":"Meng L. V. (2025). A Phase I Dose-Escalation and Phase II Study of Nanobody-Based CD5-Targeted CAR-T Cells for the Treatment of Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia\/Lymphoma (T-ALL\/LBL) - The CONQUER Trial. https:\/\/clinicaltrials.gov. Retrieved April 29, 2026, from https:\/\/clinicaltrials.gov"},{"key":"2113_CR93","unstructured":"Mei H. (2026). Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R\/ RMM. clinicaltrials.gov, NCT06874946."},{"key":"2113_CR94","unstructured":"Xin Wu. (2026). A Phase I Clinical Trial of MUC1-targeted CAR-T Cells with PD1 Nanobody MSLN Dual-target for Advanced Gynecological Solid Tumors. ClinicalTrials.gov, NCT06904131."}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02113-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02113-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02113-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:13:53Z","timestamp":1789632833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02113-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":94,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2113"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02113-0","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}